Finch Therapeutics Group, Inc.
General ticker "FNCH" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $20.5M (TTM average)
Finch Therapeutics Group, Inc. follows the US Stock Market performance with the rate: 2.0%.
Estimated limits based on current volatility of 4.8%: low 13.31$, high 14.66$
Factors to consider:
- Total employees count: 189 as of 2021
- Top business risk factors: Strategic risks and growth management, Operational and conduct risks, Cybersecurity threats, Litigation risks, Regulatory and compliance
- Current price 317.3% above estimated high
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [1.12$, 4.62$]
- 2024-12-30 to 2025-12-30 estimated range: [0.78$, 3.26$]
Financial Metrics affecting the FNCH estimates:
- Positive: with PPE of -0.1 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -565.84 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of 23.83 > -0.66
Short-term FNCH quotes
Long-term FNCH plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $18.53MM | $0.86MM | $0.11MM |
| Operating Expenses | $78.52MM | $116.45MM | $83.97MM |
| Operating Income | $-59.98MM | $-115.59MM | $-83.86MM |
| Non-Operating Income | $1.82MM | $0.95MM | $5.65MM |
| R&D Expense | $57.28MM | $52.86MM | $40.10MM |
| Income(Loss) | $-58.16MM | $-114.65MM | $-78.22MM |
| Taxes | $0.00MM | $0.00MM | $-3.46MM |
| Profit(Loss)* | $-58.16MM | $-114.65MM | $-74.75MM |
| Stockholders Equity | $202.22MM | $95.71MM | $22.89MM |
| Inventory | $9.07MM | $3.51MM | $0.00MM |
| Assets | $225.37MM | $162.94MM | $55.37MM |
| Operating Cash Flow | $-67.13MM | $-74.85MM | $-31.50MM |
| Capital expenditure | $15.98MM | $2.18MM | $0.00MM |
| Investing Cash Flow | $-15.92MM | $-2.18MM | $1.33MM |
| Financing Cash Flow | $119.11MM | $14.87MM | $-16.16MM |
| Earnings Per Share** | $-36.72 | $-72.12 | $-46.59 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.